{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:02:34Z","timestamp":1787583754989,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-024-01405-5","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:40:49Z","timestamp":1731685249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study"],"prefix":"10.1186","volume":"16","author":[{"given":"Tongpeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1405_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107:112\u201322.","journal-title":"Clin Pharmacol Ther"},{"key":"1405_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1405_CR4","doi-asserted-by":"publisher","first-page":"e005145","DOI":"10.1136\/jitc-2022-005145","volume":"10","author":"X Qu","year":"2022","unstructured":"Qu X, An G, Sui W, Wang T, Zhang X, Yang J, Zhang Y, Zhang L, Zhu D, Huang J, et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Journal For Immunotherapy of Cancer. 2022;10:e005145.","journal-title":"Journal For Immunotherapy of Cancer"},{"key":"1405_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"key":"1405_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","volume":"21","author":"C Qu","year":"2022","unstructured":"Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, Zhang L, Yi Z, Long L, Yan L, et al. Tumor buster - where will the CAR-T cell therapy \u201cmissile\u201d go? Mol Cancer. 2022;21:201.","journal-title":"Mol Cancer"},{"key":"1405_CR7","doi-asserted-by":"publisher","first-page":"867154","DOI":"10.3389\/fimmu.2022.867154","volume":"13","author":"L Antonucci","year":"2022","unstructured":"Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F. CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol. 2022;13:867154.","journal-title":"Front Immunol"},{"key":"1405_CR8","doi-asserted-by":"publisher","first-page":"936496","DOI":"10.3389\/fimmu.2022.936496","volume":"13","author":"T Yu","year":"2022","unstructured":"Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Revolution of CAR engineering for next-generation immunotherapy in solid tumors. Front Immunol. 2022;13:936496.","journal-title":"Front Immunol"},{"key":"1405_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"1405_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"1405_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"1405_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"1405_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397.","journal-title":"Annu Rev Biochem"},{"key":"1405_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Research. 2022;10:24.","journal-title":"Biomarker Research"},{"key":"1405_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"1405_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.26586","volume":"97","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang X, Zhou Z, Liu Y, Yu L, Jia L, Yang J, Li J, Yu H, Li W, et al. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. Am J Hematol. 2022;97(8):992\u20131004.","journal-title":"Am J Hematol."},{"key":"1405_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","volume":"3","author":"E Wang","year":"2015","unstructured":"Wang E, Wang L-C, Tsai C-Y, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol Res. 2015;3:815\u201326.","journal-title":"Cancer Immunol Res"},{"key":"1405_CR18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2217\/imt-2022-0171","volume":"14","author":"T Xu","year":"2022","unstructured":"Xu T, Wang C, Chen X, Bai J, Wang E, Sun M. Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy. Immunotherapy. 2022;14:1457\u201366.","journal-title":"Immunotherapy"},{"key":"1405_CR19","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","volume":"74","author":"I Pastan","year":"2014","unstructured":"Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Can Res. 2014;74:2907\u201312.","journal-title":"Can Res"},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-7-15","volume":"7","author":"J Yuan","year":"2014","unstructured":"Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014;7:15.","journal-title":"J Hematol Oncol"},{"key":"1405_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","volume":"21","author":"A Klampatsa","year":"2021","unstructured":"Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473\u201386.","journal-title":"Expert Opin Biol Ther"},{"key":"1405_CR22","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","volume":"81","author":"E Schoutrop","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, et al. Mesothelin-specific CAR T cells target ovarian cancer. Can Res. 2021;81:3022\u201335.","journal-title":"Can Res"},{"key":"1405_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","volume":"9","author":"L Castelletti","year":"2021","unstructured":"Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomarker Research. 2021;9:11.","journal-title":"Biomarker Research"},{"key":"1405_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.tibtech.2021.03.005","volume":"39","author":"R Castellanos-Rueda","year":"2021","unstructured":"Castellanos-Rueda R, Di Roberto RB, Schlatter FS, Reddy ST. Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies. Trends Biotechnol. 2021;39:1308\u201320.","journal-title":"Trends Biotechnol"},{"key":"1405_CR25","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1158\/1078-0432.CCR-19-3417","volume":"26","author":"L Zheng","year":"2020","unstructured":"Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. A humanized Lym-1 CAR with novel DAP10\/DAP12 signaling domains demonstrates reduced tonic signaling and increased antitumor activity in B-cell lymphoma models. Clin Cancer Res. 2020;26:3694\u2013706.","journal-title":"Clin Cancer Res"},{"key":"1405_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1405_CR27","doi-asserted-by":"publisher","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016.","journal-title":"Front Immunol"},{"key":"1405_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18:9\u201318.","journal-title":"Curr Hematol Malig Rep."},{"key":"1405_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood.2019004500","volume":"136","author":"L Fultang","year":"2020","unstructured":"Fultang L, Booth S, Yogev O, Martins da Costa B, Tubb V, Panetti S, Stavrou V, Scarpa U, Jankevics A, Lloyd G, et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood. 2020;136:1155\u201360.","journal-title":"Blood"},{"key":"1405_CR30","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919\u201329.","journal-title":"Mol Ther"},{"key":"1405_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72:409\u201325.","journal-title":"Cancer Immunol Immunother"},{"key":"1405_CR32","unstructured":"Xu T, Shu Y, et al. Characterization of mesothelin targeting novel multiple chain DAP-CAR-T cells efficacy in patients with ovarian cancer and mesothelioma through single-cell transcriptomic analysis. HRA006416. 2024. https:\/\/bigd.big.ac.cn."},{"key":"1405_CR33","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. Github. https:\/\/github.com\/rcastelo\/GSVA."},{"key":"1405_CR34","unstructured":"Efremova M, Vento-Tormo M, Teichmann S, Vento-Tormo R. CellphoneDB v2: inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. Github. https:\/\/github.com\/ventolab\/CellphoneDB."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01405-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-024-01405-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01405-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:03:08Z","timestamp":1731686588000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-024-01405-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1186\/s13073-024-01405-5","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institution Review Board of The First Affiliated Hospital of Nanjing Medical University (2021-SR-084). This study conformed to the principles of the Helsinki Declaration. Healthy donors or patients consented to participate in the study. All participants provided written informed consent prior to participation. The animal experiment in this study was approved by the Institutional Ethics Committee of Nanjing Medical University (IACUC2103036).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors EX-W, C-W, and JZ-Z were employed by Nanjing CART Medical Technology Co., Ltd. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}